News for Akero Therapeutics, Inc. (AKRO)

Stocks Analysis by MarketBeat.com (Sam Quirke) covering: H&E Equipment Services Inc, Akero Therapeutics Inc, Oklo Inc. Read MarketBeat.com (Sam Quirke)'s latest article on Investing.com

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc.

Strengths: Innovative lead product candidate EFX with potential to address unmet needs in MASH treatment.Weaknesses: High operational costs leading to signific

Discover Akero Therapeutics' (AKRO) Q4 results: GAAP EPS of -$0.99, surpassing expectations by $0.17.

Summary Akero Therapeutics Inc (AKRO), a clinical-stage company focused on developing treatments for serious metabolic diseases, announced significant progress

-- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in P

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc.

-- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chai

On December 31, 2024, JANUS HENDERSON GROUP PLC (Trades, Portfolio) executed a significant transaction involving Akero Therapeutics Inc (AKRO), reducing its hol

On December 31, 2024, RTW INVESTMENTS, LP (Trades, Portfolio) executed a significant transaction involving Akero Therapeutics Inc (AKRO). The firm added 940,388

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Akero Therapeutics Inc (NASDAQ:AKRO) stands against...

This is our list of the best health care stocks based on the highest return over the last 30 days.

Unsurprisingly, Akero owes this incredible one-day gain to data from a midstage clinical trial. Akero Therapeutics is developing efruxifermin as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), a non-alcohol-related liver disease. MASH is linked to a dangerous buildup of fat in the liver, leading to fibrosis (scarring of the liver) or, in some cases, a severe version known as cirrhosis.

We recently compiled a list of the 12 Best Booming Stocks to Invest in Now. In this article, we are going to take a look at where Akero Therapeutics, Inc.

This is our list of the best growth stocks based on their returns over the last 30 days.

Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics are part of the Zacks top Analyst Blog.

Discover a clinical-stage company focusing on groundbreaking treatments for patients with serious metabolic diseases.

**media[526797]**

U.S. stocks were mixed, with the Dow Jones index falling around 0.1% on Tuesday. Shares of Royal Caribbean Cruises Ltd. RCL gained 6.2% to $251.48 following a ...